This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Guidelines
    Guideline
    01/02/22

    EAACI guidelines: Anaphylaxis (2021 update)

    Understand EAACI 2021 guidelines for anaphylaxis, focusing on clinical criteria and structured training. Read more now!

    • Source: European Academy of Allergy and Clinical Immunology (EAACI)
    Guidelines
    Anaphylaxis Assessment & Referral – NICE guidelines - Medthority
    23/08/20

    Anaphylaxis: assessment and referral after emergency treatment

    The NICE guideline on anaphylaxis assessment and referral after emergency treatment provides detailed recommendations for improving care quality. It covers the necessary assessments and referrals to specialist allergy services, emphasizing the importance of prescribing adrenaline injectors before discharge.

    • Source: National Institute for Health and Care Excellence (NICE)
    Guidelines
    Guideline
    01/02/24

    Anaphylaxis: A 2023 practice parameter update (AAAAI)

    The 2023 practice parameter update by the American Academy of Allergy, Asthma & Immunology (AAAAI) focuses on new evidence and recommendations for diagnosing and managing anaphylaxis. It highlights the importance of serum tryptase measurement and specific measures for different community settings.

    • Source: American Academy of Allergy, Asthma & Immunology (AAAAI)
    Journals
    Journal
    30/09/20

    Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference

    Hyperkalemia is a common electrolyte disorder observed in the emergency department. It is often associated with underlying predisposing conditions, such as moderate or severe kidney disease, heart failure, diabetes mellitus, or significant tissue trauma.

    • Source: European Journal of Emergency Medicine
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/09/18

    FDA approves lower dose of Symjepi for the emergency treatment of allergic reactions, including anaphylaxis.- Admis Pharma

    Adamis Pharmaceuticals Corporation announced that the FDA has approved Adamis� lower dose version (0.15mg) of Symjepi for the emergency treatment...

    Guidelines
    Guideline
    26/06/25

    Consensus guidelines on the diagnosis and management of myasthenia gravis - Saudi Neurology Society

    Experts from Saudi Arabia and the Gulf Cooperation Council present consensus guidelines to support the diagnosis and management of myasthenia gravis. Using the Delphi method, the recommendations aim to guide clinical decision‑making and improve outcomes by addressing regional needs and practice gaps.

    • Source: Saudi Neurology Society
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/09/24

    European Commission approves EUR Neffy (epinephrine nasal spray) for emergency treatment of severe allergic reactions in adults and children

    ARS Pharmaceuticals, Inc. announced the European Commission's approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/02/18

    Adamis Pharmaceuticals files sNDA for Symjepi for the emergency treatment of anaphylaxis.

    Adamis Pharmaceuticals Corporation announced that the FDA has accepted for review the Company�s supplemental New Drug Application (�sNDA�) for its...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/08/24

    FDA approval of neffy (epinephrine nasal spray), the first and only needle-free treatment for type I allergic reactions, including anaphylaxis

    ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced that the FDA approved neffy (epinephrine nasal spray) 2 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ?30 kg (66 lbs.)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/08/24

    FDA approval of neffy (epinephrine nasal spray), the first and only needle-free treatment for type I allergic reactions, including anaphylaxis

    ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced that the FDA approved neffy (epinephrine nasal spray) 2 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than 30 kg (66 lbs.)

    See more